The packet does not list certified causative genes for Alport syndrome, so no gene is named here, and the inheritance pattern field is empty. The disease subtypes in the packet are named according to X-linked, autosomal dominant, autosomal recessive, and digenic forms. GeneReviews notes that digenic inheritance has been described and that, for the autosomal dominant form, penetrance is reduced and severity varies greatly even within the same family, with some heterozygous individuals asymptomatic and some developing end-stage kidney disease.

GeneReviews states that diagnostic criteria for Alport syndrome have been published and lists suggestive findings. The clinical findings are sensorineural deafness, anterior lenticonus and/or characteristic retinopathy, and diffuse leiomyomatosis, appearing together with persistent glomerular hematuria. Family history findings include hematuria, chronic kidney disease or kidney failure, and deafness associated with chronic kidney disease. Pathologic findings on kidney biopsy include negative or nonspecific routine immunofluorescence, abnormal type IV collagen expression, thin glomerular basement membranes, and characteristic glomerular basement membrane thickening, lamellation, and scalloping. GeneReviews describes a molecular diagnosis as established when suggestive findings are accompanied by pathogenic or likely pathogenic variants identified through molecular genetic testing, using a multigene panel or comprehensive genomic testing, and notes that variants of uncertain significance cannot confirm or rule out the diagnosis.

The packet contains no FDA approval records for Alport syndrome, so no current FDA-approved option is certified here. The orphan drug listing includes DESIGNATED records for bardoxolone methyl, ivaltinostat, setanaxib, and vonafexor, among others, and a WITHDRAWN record for a microRNA-21 inhibiting oligonucleotide; a designation is not an approval or a statement of availability. GeneReviews describes treatment of manifestations as follows: for kidney disease, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, standard management of hypertension, and kidney transplantation for end-stage kidney disease; for hearing deficit, hearing aids; for vision issues, cataract removal; and for diffuse leiomyomatosis, surgical intervention for symptomatic leiomyomas. It also states that early intervention is aimed at suppressing proteinuria using angiotensin antagonists. These entries describe what the source documents and do not indicate suitability for any individual.

GeneReviews reports that outcomes differ by form and, in the X-linked form, by sex and variant type. It estimates that 50% of males with the X-linked form reach end-stage kidney disease by age 35 years and gives a median age of 65 years for end-stage kidney disease in X-linked females. Most individuals with the autosomal recessive form are described as developing significant proteinuria in childhood and end-stage kidney disease before age 30 years. Progression is described as slower in the autosomal dominant form, frequently delayed until later adulthood. In affected males hearing loss is described as progressive. These figures are population-level estimates from the source and vary across forms and individuals.

The packet lists registered ClinicalTrials.gov studies for Alport syndrome. NCT07523581 is a phase 2 study titled as evaluating exaluren efficacy and safety, sponsored by Eloxx Pharmaceuticals, Inc. and listed as recruiting. NCT07211685 is a phase 2 study of BAY 3401016 in adults, sponsored by Bayer and listed as active, not recruiting. NCT06731192 is a phase 2 study of human umbilical cord mesenchymal stem cells sponsored by Guangzhou Women and Children's Medical Center, listed as not yet recruiting. NCT06526741 is the ASF Alport Patient Registry, sponsored by the Alport Syndrome Foundation and recruiting. NCT02378805 is an Alport therapy registry sponsored by University Hospital Goettingen and recruiting, and NCT05927467 is a French cohort sponsored by Institut National de la Santé Et de la Recherche Médicale. Study titles do not establish the interventions tested or any efficacy.